In a report released on March 26, Yatin Suneja from Guggenheim reiterated a Buy rating on Zura Bio (ZURA – Research Report), with a price ...

Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...

Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following yesterday’s topline data from the Batoclimab ...

We recently published a list of 10 Best Stocks to Buy According to Billionaire David Einhorn. In this article, we are going ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

Sanofi, AbbVie, Johnson & Johnson (J&J), and other global pharmaceutical companies are opening their wallets to develop new treatments for autoimmune diseases. Autoimmune diseases occur when ...

Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.